Label-free methods using a resonant waveguide grating biosensor to determine GPCR signaling pathways

• US 8,426,148 B2
• Filed: 11/30/2007
• Issued: 04/23/2013
• Est. Priority Date: 10/06/2007
• Status: Expired due to Fees

• Current Assignee: Corning Incorporated
• Original Assignee: Corning Incorporated
• Inventors: Fang, Ye, Gao, Y. Alice, Tran, Elizabeth
• Primary Examiner(s): LANDSMAN, ROBERT S
• Application Number:
  US11/998,711
• Publication Number:
  US 20120135423A1
• Time in Patent Office: 1,971 Days
• Field of Search: None
• US Class Current: 435/7.21
• CPC Class Codes: G01N 2333/726 G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
• CPC Class Codes: G01N 33/54373 involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
• CPC Class Codes: G01N 33/554 the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
• CPC Class Codes: G01N 33/74 involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Abstract

A system and method for GPCR signaling pathway analysis and elucidation using a biosensor, a live-cell, and a pathway active compound, as defined herein.

Claims

1. A label-free method for GPCR signaling pathway determination, the method comprising:

immobilizing live cells on a resonant waveguide grating (RWG) biosensor;

contacting the immobilized live cells with a substance that elevates intracellular cAMP and activates protein kinase A in the live cells;

contacting the substance-contacted live cells with a GPCR ligand;

detecting and comparing the GPCR ligand-induced biosensor response of the live cells in the presence and absence of the substance; and

determining the signalling pathways of the GPCR activated by the ligand, wherein the substance-induced inhibition of the GPCR ligand-induced response indicates that the GPCR signals via G<sub>α

s</sub> pathway, the substance-induced partial suppression of the GPCR ligand-induced response indicates that the GPCR signals via a G<sub>α

q</sub> pathway, and the substance-induced potentiation of the GPCR ligand-induced response indicates that the GPCR signals via a G<sub>α

i</sub> pathway, wherein the response is a dynamic mass redistribution (DMR) signal measured by the resonant waveguide biosensor, and the substance is a probe molecule to differentiate all classes of signalling mediated through the GPCR.

2. The method of claim 1 wherein the substance comprises an adenylate activator.

3. The method of claim 2 wherein the adenylate activator comprises at least one of forskolin, NKH477, 1,9-dideoxy-forskolin, 7-deacetyl-7-O-hemisuccinyl-forskolin, or combinations thereof.

4. The method of claim 1 wherein the substance comprises a cell-permeable cAMP analog.

5. The method of claim 4 wherein the cell-permeable cAMP analog comprises at least one of (S)-adenosine, cyclic 3′

,5′

-(hydrogenphosphorothioate)triethyl ammonium, 8-bromoadenosine- 3′

,5′

-cyclic monophosphate, 8-chloroadenosine- 3′

,5′

-cyclic monophosphate, N6, 2′

-O-dibutyryladenosine-3′

, 5′

-cyclic monophosphate, or a combination thereof.

6. The method of claim 1 wherein the GPCR ligand comprises at least one of an agonist, a partial agonist, or an inverse agonist that mediates signaling through a receptor expressed in the live cells.

7. The method of claim 1 wherein contacting the immobilized live cells with the substance first causes intracellular cAMP elevation and second causes protein kinase A activation.

8. The method of claim 1 wherein immobilizing live cells on a biosensor comprises incubating live-cells on a biosensor surface to a confluency of from about 1 percent to about 99 percent biosensor surface coverage.

9. The method of claim 1 wherein the elevated intracellular cAMP level has partial inhibition effect on G_q or G_12/13 signaling, completely attenuates G_s signaling through heterologous desensitization, enhances G_i signaling induced by an agonist at its EC₅₀ concentrations for the receptor through heterologous sensitization, and permits de-convolution and determination of live cell GPCR signalling, wherein the EC₅₀ of the agonist for the receptor is determined via dose-dependent dynamic mass redistribution measurement with the label-free RWG biosensor.

10. The method of claim 1 further comprising combining a phospholipase C suppressor with the adenylate cyclase activator.

11. The method of claim 1 further comprising at least one of a pretreatment, an intermediate treatment, a post-treatment, or a combination thereof of the immobilized live cells with a stimulus.

12. The method of claim 1 wherein the alteration of the GPCR ligand-induced biosensor response induced by the substance is indicative of the signalling pathway being activated by the ligand, wherein the signalling pathway being activated is at least one of Gq, Gi, Gs, G_12/13, or a combination thereof.

13. The method of claim 1 wherein the alteration of the GPCR ligand-induced biosensor response by the substance differentiates among different classes of G protein signaling, differentiates between signaling of GPCRs and signaling of non-GPCRs, or both.

14. A method for GPCR signaling pathway determination, the method comprising:

immobilizing live cells on a resonant waveguide grating (RWG) biosensor;

contacting the immobilized live cells with a GPCR ligand;

contacting the GPCR ligand-contacted live cells with a substance that elevates intracellular cAMP and activates protein kinase A in the live cells;

detecting and comparing the substance-induced biosensor response of the live cells in the presence and absence of the GPCR ligand; and

determining the signal pathway of the GPCR induced by the ligand, wherein the alteration of the substance-induced response by the ligand indicates the signalling pathway being activated by the ligand, the substance-induced response is a dynamic mass redistribution response, and the substance is a probe molecule to differentiate all classes of signalling mediated through the GPCR.

15. The method of claim 14 wherein the GPCR is the endogenous nicotinic acid receptor HM74a expressed in human epidermoid A431 cells.

16. The method of claim 14 wherein the GPCR ligand comprises at least one of an agonist, a partial agonist, an inverse agonist that mediates signaling through the GPCR expressed in the live-cells, or a combination thereof.

17. A method for GPCR signaling pathway determination, the method comprising:

immobilizing live cells on a resonant waveguide grating (RWG) biosensor;

contacting the immobilized live-cells with a substance that suppresses intracellular phospholipase C (PLC) activity in the live cells;

contacting the PLC-suppressed live cells with a GPCR ligand;

detecting and comparing the GPCR ligand-induced biosensor response of the live cells in the presence and absence of the substance; and

determining the GPCR signal pathway of the receptor induced by the ligand, wherein the inhibition of the GPCR ligand-induced response indicates that the GPCR signals via G<sub>α

q</sub> pathway, the substance-induced partial suppression of the GPCR ligand-induced response indicates that the GPCR signals via a G<sub>α

i</sub> pathway, the substance-induced little change of the GPCR ligand-induced response indicates that the GPCR signals via a G<sub>α

s</sub> pathway, and the substance is a probe molecule to differentiate all classes of signalling mediated through the GPCR.

18. The method of claim 17 wherein the substance that suppresses intracellular phospholipase C (PLC) activity in the live-cells comprises a PLC inhibitor, a PLC gene suppressor interference RNA, or a combination thereof.

19. The method of claim 18 wherein the PLC inhibitor comprises U73122.

20. The method of claim 19 wherein the suppression of PLC activity has limited effect on G_s, or G_12/13 signaling, completely attenuates G_q signaling, and partially attenuates G_i, signaling;

and permits de-convolution and determination of live-cell GPCR signaling.